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The oncogene product MDM2 can be phosphorylated by
protein kinase CK2 in vitro 0.5 – 1 mol of phosphate
were incorporated per mol MDM2 protein. The catalytic
subunit of protein kinase CK2 (a-subunit) catalyzed the
incorporation of twice as much phosphate into the
MDM2 protein as it was obtained with the holoenzyme.
Polylysine stimulated MDM2 phosphorylation by CK2
holoenzyme threefold in contrast to the a-subunit-
catalyzed MDM2 phosphorylation which was reduced
by about 66% when polylysine was added. Full length
p53, but also a peptide representing a C-terminal
fragment of the tumor suppressor gene product p53
(amino acids 264 – 393 which also harbors the CK2b
interaction site at amino acids 287 – 340) mimicked the
polylysine eect in all respects, ie. stimulation of
phosphate incorporation by CK2 holoenzyme and
inhibition in the presence of the catalytic CK2 a-subunit.
Stimulation by p53264– 393 was on the average close to
twofold and inhibition in the case of the a-subunit-
catalyzed MDM2 phosphorylation was about 40%.
Phosphorylation of MDM2 by CK2 holoenzyme in the
presence of the p21WAF1/CIP1, known to be a potent
inhibitor of cyclin-dependent protein kinases, also led
to a significant reduction of phosphate incorporation into
MDM2 indicating that p21WAF1/CIP1 does not exclusively
inhibit cell cycle kinases. Furthermore, these data add
new insight into the autoregulatory loop which include
p21WAF1/CIP1, MDM2 protein, CK2 and p53.
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Introduction
The mdm2 gene was originally identified as a highly
amplified gene present on double minutes in a
spontaneously transformed tumorigenic derivative of
a Balb/c cell line called 3T3DM (Cahilly-Snyder et al.,
1987). Overexpression of the mdm2 gene in BALB/c
3T3 cells confers tumorigenicity in nude mice
(Fakharzadeh et al., 1991). Later also the correspond-
ing human mdm2 gene was identified (Oliner et al.,
1992). The mdm2 gene encodes a 490 amino acid
protein which binds to the p53 protein and is thought
to function as a regulator of p53. The MDM2 protein
binds to a region in the N-terminus of p53 representing
the transcription activation domain of p53 (Chen et al.,
1993; Oliner et al., 1992). Overexpression of MDM2
protein inhibits both the transcriptional activation and
the repression activities of p53 (Chen et al., 1995;
Momand et al., 1992). Thus overexpression of MDM2
protein results in a similar eect to mutational
inactivation of p53. p53 can induce the expression of
mdm2 gene via p53 binding site in the promoter of the
mdm2 gene, suggesting an autoregulatory feed back
loop in p53 regulation (Picksley and Lane, 1993; Wu et
al., 1993). The argument that MDM2 plays a critical
role in regulating p53 is strengthened by the over-
expression of the MDM2 protein in human sarcomas
and other tumor types. The amplification of MDM2
occurred only in the absence of p53 mutation
supporting the idea that amplification and p53
mutation are alternative mechanisms of p53 dysfunc-
tion (Reifenberger et al., 1993; Leach et al., 1993).
However, Cordon-Cardo et al. (1994) could show that
amplification of MDM2 can also occur in the presence
of p53 mutations, although less frequently.
Protein kinase CK2 is a pleiotropic serine/threonine
kinase which has been shown to phosphorylate
numerous substrates. Its ubiquity in eukaryotes and
the very high conservation of its amino acid
composition from yeast to man strongly suggests a
vital role in cellular metabolism (for reviews: see Pinna,
1990; Tuazon and Traugh, 1991; Issinger, 1993;
Allende and Allende, 1995). The enzyme has been
shown to be elevated in rapidly growing cells (for
review see: Issinger and Boldyre, 1992). Among the
many CK2 phosphosubstrates, the tumor suppressor
gene product p53 was identified (Meek et al., 1990;
Herrmann et al., 1991). In addition it was shown that
CK2 and p53 associate in a molecular complex (Filhol
et al., 1992; Kraiss et al., 1990; Herrmann et al., 1991;
Wagner et al., 1994).
Subsequently it was shown that the b-subunit of
CK2 binds to a C-terminal domain of p53 (Appel et
al., 1995) and that p21WAF1/CIP1 interacts with protein
kinase CK2 down regulating CK2 activity with respect
to the phosphorylation of its regulatory b-subunit,
casein and the C-terminus of p53 (Go¨tz et al., 1996).
Hence, there are at least five major observations
prompting the experiments conducted in this study: (i)
CK2 preferably phosphorylates proteins with a
consensus sequence S/TXXD/E, which is present to a
large extent in the MDM2 protein; (ii) CK2 interacts
with p53 (Filhol et al., 1992; Herrmann et al., 1991);
(iii) oncogene product MDM2 interacts with tumor
suppressor gene product p53 (Picksley and Lane, 1993;
Oliner et al., 1993). (iv) p21WAF1/CIP1 interaction with
CK2b abrogates phosphorylation of p53 (Go¨tz et al.,
1996) and (v) protein kinase CK2 holoenzyme has been
shown to be stimulated by polyamines such as
polylysine (Meggio et al., 1992). Polylysine abrogates
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the negative regulatory eect for certain CK2
substrates such as calmodulin. From the amino acid
sequence it was deduced that MDM2 protein has 20
potential CK2 phosphorylation sites and therefore we
wanted to answer the question whether MDM2 protein
was also a substrate for CK2 and furthermore would it
behave as most of the known CK2 substrates or would
it be more of a calmodulin-type substrate. Initially full
length p53 was used but could be replaced by a
carboxy-terminal fragment of p53 to study its eect on
the phosphorylation of MDM2 protein by CK2. This
proved to be more convenient without questioning the
results obtained with full length p53 because: Firstly
the carboxy terminus of p53264 – 393 contains the
interaction site with the regulatory b-subunit of CK2,
(ii) it contains the CK2 phosphorylation site S392 and
(iii) the C-terminal sequence harbors a high percentage
of basic residues which appear partially in clusters, and
thus could possibly mimick a polylysine eect.
Results
Phosphorylation of MDM2 by protein kinase CK2
holoenzyme
It is known that MDM2 protein interacts with p53
(Oliner et al., 1993). p53 interacts with the b-subunit of
protein kinase CK2 (Appel et al., 1995) and
furthermore is phosphorylated by it at serine residue
392 (Meek et al., 1990). In order to see whether
MDM2 could be a suitable substrate for CK2 we
analyzed the in vitro phosphorylation of MDM2 by
protein kinase CK2 in the presence of [g-32P]ATP as
phosphate donor. Figure 1, lane a, represents a
Coomassie blue stained MDM2 protein. The relative
purity of it was determined by densitometric analysis
and the stoichiometric calculations were based on these
evaluations. Lanes b and c are controls; CK2
holoenzyme was incubated in the presence of
[g-32P]ATP (lane b) and lane c shows the result of the
incubation of MDM2 in the presence of [g-32P]ATP. In
the case of the holoenzyme we see the autophos-
phorylation of the CK2b subunit. Incubation of the
MDM2 protein in the presence of [g-32P]ATP does not
lead to any phosphorylation indicating that no
contaminating protein kinase activity was present in
our MDM2 preparation. In the presence of the CK2
holoenzyme, MDM2 was strongly phosphorylated
(lane d) in addition to the auto-phosphorylation of
the CK2b-subunit. Incorporation of phosphate into
MDM2 protein varied between 0.5 – 1 mol/mol at 378C
in 30 min.
Next we wanted to see whether addition of
polylysine would lead to a stimulatory eect (Meggio
et al., 1987). For a control, protein kinase CK2
holoenzyme was incubated in the presence of poly-
lysine. Again, as already well known (Boldyre et al.,
1994) we observed autophosphorylation of the catalytic
CK2a-subunit (lane e). Addition of polylysine to the
CK2 holoenzyme and MDM2 protein led to a 2.5 – 3-
fold stimulation of MDM2 phosphate incorporation
(lane f). From these results we conclude that MDM2 is
another CK2 substrate ie. it was phosphorylated by
protein kinase CK2 in the absence of polylysine,
polylysine only enhanced the phosphorylation whereas
heparin inhibited MDM2 phosphorylation (results not
shown).
Phosphorylation of MDM2 using CK2a
In order to investigate the behaviour on MDM2
phosphorylation of CK2a-subunit we carried out a
phosphorylation experiment incubating the oncopro-
tein in the presence of the catalytic subunit of CK2 and
[g-32P]ATP as phosphate donor. The responsiveness of
the recombinant CK2a-subunit was then compared to
that of CK2 holoenzyme. Figure 2, lane a, shows the
phosphorylation of MDM2 by CK2a. Three moles
phosphate/mol MDM2 protein were incorporated
about twice as much as it is the case when the CK2
holoenzyme was used (Figure 1, lane d). Addition of
polylysine led to a reduction of phosphate incorpora-
tion by 60% (lane b) reducing phosphate incorporation
to 1 mol/mol MDM2.







Figure 1 Phosphorylation of MDM2 by protein kinase CK2
holoenzyme. Lane a shows a Coomassie-stained MDM2 protein
and an autoradiograph of a phosphorylation experiment (lanes
b – f). Lane b shows the autophosphorylation of CK2, lane c
shows only MDM2 without any protein kinase added, lane d is
MDM2 in the presence of CK2 holoenzyme, lane e holoenzyme in





Figure 2 Phosphorylation of MDM2 using CK2a. Autoradio-
graphy showing phosphorylation of MDM2 by CK2a. Lane a
MDM2 in the presence of CK2a, lane b MDM2 in the presence
of CK2a and polylysine
MDM2 phosphorylation by CK2
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Phosphorylation of MDM2 by CK2 holoenzyme and the
a-subunit, in the presence of p53264 – 393
Protein kinase CK2 is known to bind to the tumor
suppressor protein p53 (Wagner et al., 1994) and the
binding domain on the polypeptide chain of p53 is
situated between amino acids 287 – 340 (Appel et al.,
1995). The carboxy terminus of p53 contains a high
percentage of basic residues which may mimick a
possible polylysine-like eect on MDM2 phosphoryla-
tion by protein kinase CK2. Therefore we analyzed the
in vitro phosphorylation of MDM2 by protein kinases
CK2 holoenzyme and CK2a-subunit in the absence
and presence of a C-terminal fragment of p53: CT264– 393
(Figure 3). All c.p.m. values counted by the Instant
Imager (Packard) were normalized and expressed as
percentages using the corresponding values obtained
for CK2 holoenzyme and CK2a-subunit alone as
100%. When p53264– 393 was added the CK2 holoen-
zyme-catalyzed MDM2 phosphorylation increased
between 1.4 – 3.7-fold (a paired t-test revealed a two-
tailed P value of 0.0251) which shows that the observed
dierences are significant. We have measured the
influence of dierent p53264 – 393 concentrations on
MDM2 phosphorylation. Saturation was reached at
500 ng. In the presence of CK2a-subunit-catalyzed
MDM2 phosphorylation we observed a 39% reduction
(a similar two-tailed P value ie. 0.024, was also
obtained here) when comparing the reduction of
MDM2 phosphorylation in the presence of the p53
peptide compared to its absence. Initial experiments
using full length p53 also stimulated phosphorylation
of MDM2 by CK2 holoenzyme and also led to a
comparable reduction in MDM2 phosphorylation
when the catalytic subunit was used (results not
shown). When an N-terminal fragment of p53 was
used, comprising amino acids 1 – 287 (lacking the
CK2b binding site) and which also is not phosphory-
lated by the CK2 holoenzyme no stimulation of CK2-
catalyzed MDM2 was observed (results not shown).
When casein or the synthetic peptide were used as
substrates for CK2 holoenzyme or CK2a-subunit no
significant stimulatory or inhibitory eect of the p53
peptide was observed (results not shown).
Abrogation of MDM2 protein phosphorylation by CK2
in the presence of p21WAF1/CIP1
Recently a new binding partner for the regulatory b-
subunit of CK2 (Go¨tz et al., 1996) was found, namely
p21WAF1/CIP1. This protein is a potent inhibitor of cyclin-
dependent kinases (Harper et al., 1994) and is
transactivated in a p53-dependent manner (El Deiry
et al., 1993, 1994). Bearing in mind the down
regulatory eect of p21WAF1/CIP1 on protein kinase CK2
activity with respect to the autophosphorylation and
phosphorylation of p53 C-terminus we wanted to
analyse a possible eect of p21WAF1/CIP1 on phosphoryla-
tion of MDM2 in the presence of protein kinase CK2.
In Figure 4, lanes a and c represent controls,
respectively, ie. phosphorylation of MDM2 by CK2
holoenzyme and CK2 autophosphorylation. Lane b
shows the eect of p21WAF1/CIP1 on MDM2 phosphor-
ylation by CK2 holoenzyme.
It can be clearly seen that in the presence of p21WAF1/
CIP1, the phosphorylation of MDM2 protein is reduced
indicating that the p21WAF1/CIP1 protein exerts an
inhibitory eect on protein kinase CK2 with respect






Figure 4 Abrogation of MDM2 protein phosphorylation by
CK2 in the presence of p21WAF1/CIP1. Autoradiography showing
phosphorylation of MDM2 by CK2 holoenzyme (lane a) and in
lane b CK2-catalyzed MDM2 phosphorylation in the presence of
p21WAF1/CIP1. Lane c autophosphorylation of CK2
Figure 3 Phosphorylation of MDM2 by CK2 holoenzyme and
the a-subunit, in the presence of p53264 – 393. Bar graph showing
the influence of the p53 fragment on MDM2 phosphorylation by
CK2 holoenzyme and CK2a. The radioactivity incorporated into
MDM2 protein in the absence of p53 peptide was set 100%. The
obtained incorporation of radioactivity after the addition of p53
fragment either in the presence of CK2 holoenzyme or CK2a was
calculated and then expressed as percent in relation to the 100%
value. The values expressing the influence of the p53 peptide on
CK2 holoenzyme catalyzed MDM2 phosphorylation are the mean
of four independent experiments
MDM2 phosphorylation by CK2
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Discussion
The tumor suppressor gene product p53 has drawn
considerable attention in tumor research in recent
years. The p53 protein has been shown to be a negative
regulator of cell growth, an inhibitor of cellular
transformation (for review see: Selter and Montenarh,
1994) and an inducer for programmed cell death (for
review see: Go¨tz and Montenarh, 1995). Whereas in
the beginning the mutated form of this protein was
considered to be the major cause leading to a loss of
normal function other ways leading to loss of function
are now emerging including secondary modification,
eg. by phosphorylation or interaction with other
proteins (Pietenpol and Vogelstein, 1993). Observa-
tions which showed the existence of p53/MDM2 and
p53/CK2 complexes are the basis to demonstrate also a
possible CK2-MDM2 connection, especially since
MDM2 harbors many CK2 consensus sequences. The
data shown here confirm the original speculations.
CK2 phosphorylates MDM2 protein stoichiometrically
and furthermore the phosphate incorporation can be
increased in the presence of polylysine. Since MDM2
phosphorylation occurs also in the absence of
polylysine it behaves like most CK2 substrates. In
order to replace the ‘artificial’ polybasic modulator by
a more ‘natural’ molecule we analysed the CK2-
catalyzed MDM2 phosphorylation in the presence of
a full length p53 or for convenience reasons a p53
peptide covering the carboxy terminal amino acids
264 – 393. When an N-terminal fragment of p53 was
used comprising amino acids 1 – 287 (lacking the CK2b
binding site) which is not phosphorylated by the CK2
holoenzyme no stimulation of CK2-catalyzed MDM2
was observed (results not shown). This result shows
that the p53 carboxy terminus is responsible for the
stimulatory eect of the CK2 holoenzyme-catalyzed
MDM2 phosphorylation. Since the p53 peptide 264 –
393 contains the CK2/p53 interaction site together with
the polybasic amino acid stretch it is very likely that
both are required for the observed stimulatory eect.
This makes sense given the results obtained with the
full length p53 molecule. The full length p53 molecule
is simply too large and too heterogenous to act as a
polycation solely, comparable to polylysine. Therefore,
we postulate that the specific binding of p53 via its
known CK2/p53 interaction domain, resulting in a
CK2/p53 complex brings the polybasic carboxy
terminus into the vicinity of a basic charge environ-
ment in CK2 mimicking the polylysine eect. This
postulation is supported by observation from Guerra
and Issinger (unpublished results) where it is shown
that Ki-ras, which harbors a very distinct polybasic
carboxy terminal stretch (amino acids 172 – 182), does
not stimulate MDM2 phosphorylation by the CK2
holoenzyme and indeed Ki-ras has never been shown
to interact with CK2 supporting the notion that a
specific interaction site with CK2 is a prerequisite for
the action of a polybasic amino acid stretch.
Phosphorylation of p53 by CK2 has no influence on
MDM2 binding (Momand and Zambetti, 1996). Olson
et al. (1993) had shown that phosphorylated MDM2 is
still found in a complex together with p53. Given the
fact that MDM2 harbors an extraordinary number of
possible phosphorylation sites we assume that it is not
the overall phosphorylation one has to consider but
that it is rather a detailed and specific phosphorylation
site which is important for specific interaction with
p53. Further investigations will be needed to explore
the in vivo phosphorylation status of MDM2. This will
then allow to throw light onto the role of CK2 in vivo
phosphorylation of MDM2.
The C-terminus of p53 harbors the major nuclear
localization signal (amino acids 310 – 319) (Addison et
al., 1990; Shaulsky et al., 1990) a non-specific DNA
binding motif (amino acids 343 – 390) (Foord et al.,
1991) and the minimal transformation domain
(Shaulian et al., 1992; Wang et al., 1993; Unger et
al., 1993), the region for the self oligomerization
(Stu¨rzbecher et al., 1992) and for binding to various
proteins (Appel et al., 1995; Wagner et al., 1994;
Harris, 1996). Loss of oligomerization of p53 correlates
with loss of transformation activity of p53 (Slingerland
et al., 1993). p53 catalyzes the annealing of comple-
mentary DNA and RNA strands (Oberosler et al.,
1993; Bakalkin et al., 1994) and this activity is
inhibited by complex formation of p53 with CK2
(Filhol et al., 1996). Thus, C-terminal sequences are
implicated in protein – protein interaction and these
interactions lead to altered biological activities of the
aected cellular proteins. p53 is phosphorylated by
several protein kinases in vivo and in vitro (Meek and
Eckhart, 1990; Meek et al., 1990; Herrmann et al.,
1991; Milne et al., 1995; Milne et al., 1994, 1996; Lees-
Miller et al., 1990, 1992). It was previously shown that
phosphorylation of p53 by CK2 at residue 392 is
critical for the interaction of p53 with the b-subunit
(Filhol et al., 1992). However, we have shown that this
is clearly not the case for the C-terminal fragment of
p53 which shows no dierence in binding to
phosphorylated or unphosphorylated p53 (Appel et
al., 1995). By replacing the potential serine-threonines
of the CK2 consensus sequences in the p53 peptide
through alanines we excluded the possibility that other
eects apart from solely binding may be responsible for
the stimulatory eect of the p53 peptide on MDM2
phosphorylation. Furthermore this peptide does not
contain the MDM2 binding site (which is located in the
amino terminal end) but shows several basic amino
acid clusters (Soussi et al., 1990), hence it could well
surrogate the polylysine eect. As we could show this
was indeed the case. Phosphate incorporation into
MDM2 increased after the addition of p53264 – 393, albeit
not to the same extent as it was found with polylysine.
Interestingly enough the p53 peptide was not capable
of counteracting the negative regulatory eect of the
CK2b-subunit when calmodulin was used as substrate
for CK2 (results not shown). The inability of the p53
peptide to exert the polylysine eect when casein and
the synthetic peptide were used instead of MDM2 as
substrates may reflect a certain specificity of the p53
peptide towards MDM2 phosphorylation. So either
we have to postulate another, maybe weaker interac-
tion or that casein and the synthetic peptide
(RRRDDDSDDD) are so excellent – albeit artificial
substrates – for CK2 that the observed eect of the
p53 peptide with MDM2 as a substrate cannot be
detected with casein and the synthetic peptide.
MDM2 is a phosphoprotein (Olson et al., 1993) yet,
we do not know whether CK2-catalyzed phosphoryla-
tion of MDM2 occurs also in vivo. However, the fact
that there are several excellent CK2-specific phosphor-
MDM2 phosphorylation by CK2
B Guerra et al
2686
ylation sites in the MDM2 protein and that the
phosphorylation by CK2 is stoichiometric supports
the notion that CK2-catalyzed MDM2 phosphoryla-
tion might play a possible role in complex formation
with p53. Another product of a p53 transactivated gene
namely p21WAF1/CIP1 is a poor substrate for protein
kinase CK2. However, p21WAF1/CIP1 down regulates
phosphorylation of p53, casein and the autopho-
sphorylation of the b-subunit of CK2. In the present
study we demonstrate that p21WAF1/CIP1 also down-
regulates the phosphorylation of MDM2 by CK2.
The I0.5, ie. the concentration of p21WAF1/CIP1 required
for 50% inhibition of CK2 activity was determined to
be 361076 M. Shim et al. (1996) had found that
p21WAF1/CIP1 acts as a non-enzymatic inhibitor of stress
kinases. The observation that p21WAF1/CIP1 also can act
as an inhibitor of CK2 suggests it has several
biochemical activities beside the ones originally
described (El-Deiry et al., 1993; Harper et al., 1994).
Thus, regulation of the phosphorylation of MDM2 by
p21WAF1/CIP1 and CK2 may be part of the autoregulatory
loop described for MDM2 (Picksley and Lane, 1993;
Wu et al., 1993).
p53 binds to the CK2b subunit in the CK2
holoenzyme complex (Appel et al., 1995). We know
that the CK2 phosphorylation site in p53 is not a
common S/TXXD/E site and hence may be out-
competed in the presence of a better substrate, eg.
MDM2. Therefore one could envisage a ternary
enzyme/substrate complex between CK2/p53 and
MDM2 where phosphorylation of MDM2 is enhanced
by the cluster of basic amino acid residues of the p53
carboxyterminus. Amino acid residues 19 – 102 from
the MDM2 protein (of a total of 491) and amino acid
residues 1 to 52 of the p53 protein (of a total of 393)
are required to form p53-MDM2- complexes (Cahilly-
Snyder et al., 1987), and therefore we could exclude an
interaction between MDM2 and p53 which may have
an influence on the phosphorylation of MDM2 by
CK2. In contrast in the case of p53/CK2, the
interaction site in p53 is located in the carboxy
terminal domain. Beside p53-MDM2-complexes Mare-
chal et al. (1994) found a complex of 5S RNA-L5-
MDM2-p53. Interestingly L5/CK2b interaction was
found in the two-hybrid system screening a HeLa
cDNA library, using CK2b as a bait (Boldyre et al.,
1995) which may support the notion of CK2 or CK2b
subunit involvement in complex formation with p53/
MDM2/L5. Recent data from Momand and Zambetti
(1996) strongly suggest that phosphorylation of p53
does not control complex formation with MDM2,
however, nothing is known about the influence of the
phosphorylation of MDM2 on complex formation
between MDM2 and p53. It was suggested that p53-
MDM2 complex formation was controlled by a
posttranslational event other than p53 phosphoryla-
tion. Hence, we suggest that the CK2 binding to p53 is
the first step, followed an enzyme substrate interaction
with MDM2.
Another scenario could be that MDM2 becomes
phosphorylated by CK2 and then can bind to p53. The
presence of p53 would then enhance CK2-catalyzed
phosphorylation thus stabilizing the MDM2/p53
complex. Further experiments in this direction will
have to be done in order to explain the presence of free
p53 and free MDM2 in various cell lines (Momand
and Zambetti, 1996). Since phosphorylation of p53 is
no prerequisite for MDM2 binding, posttranslational
modification such as the observed MDM2 phosphor-
ylation by CK2 or accessory proteins (eg. L5) may
regulate p53-MDM2 complex formation.
Materials and methods
Purification of protein kinase CK2 holoenzyme and CK2a
The a and b-subunits of protein kinase CK2 were expressed
separately in a bacterial expression system (pT7-7/BL21
(DE3)). The bacterial pellets were mixed in a 1 : 1 ratio and
then purified according to Grankowski et al. (1991) with
the following modifications. The S-I fraction, 1100 mg
protein, was loaded onto a P11 phosphocellulose column
(150 ml) and was equilibrated with buer A containing
300 mM NaCl (buer A, 25 mM Tris-HCl pH 8.5, 7 mM 2-
mercaptoethanol, 0.2 mM phenylmethylsulfonyl fluoride,
PMSF). A linear gradient of 26500 ml in the range of
300 – 1000 mM NaCl in buer A was applied. Active
fractions (260 mg) eluting at approximately 700 mM
NaCl, were collected, concentrated and equilibrated with
25 mM Tris-HCl pH 8.5, 1 M NaCl and loaded onto
Superose 6 (Pharmacia). After gel filtration, the peak
fractions were collected, concentrated and dialysed against
100 mM NaCl in buer A. The total yield of the CK2
preparations was 10 – 15 mg from 20 g bacterial cells.
Phosphorylation assay with MDM2
The phosphorylation assay mix contained 1 mg MDM2
protein, 0.1 mU CK2 (1 U is the amount of protein kinase
catalyzing the transfer of 1 mmole phosphate/min to the
specific substrate) at 378C for 30 min in a final volume of
12 ml in the presence of 25 mM Tris-HCl pH 8.5, 150 mM
NaCl (in the case of CK2) or 20 mM NaCl, 5 mM MgCl2,
1 mM DTT, 50 mM [32P]-g-ATP (specific activity 1000 –
2000 c.p.m./pmol). For the evaluation of [32P] incorpo-
rated, the reaction was stopped by adding SDS sample
buer (0.14 M Tris-HCl, pH 6.8, 5.7% SDS, 12 mM DTT,
14% glycerol, 0.02% bromophenol blue) and aliquots
were subjected to SDS – PAGE. The dried gels were then
exposed to autoradiography and measured in an Instant
Imager apparatus (Packard;) alternatively the radioactive
bands were excised and measured in a liquid scintillation
counter.
Protein determination
Protein concentration was determined by the method of
Bradford (1976) using bovine serum albumine as standard.
Plasmids and protein expression
The cDNA of p21WAF1/CIP1, the cDNAs of C-terminal
fragments of human p53 and the cDNA of mouse mdm2
were cloned into the bacterial expression vector pQE-30
(Qiagen) (Appel et al., 1995). All constructs possess a tag
of six histidine residues for a one step purification by metal
chelate chromatography and the phosphorylation site for
cAMP-dependent protein kinase.
Protein purification of MDM2
Cells were harvested after a 3 h induction and resuspended
in lysis buer (6 M guanidine hydrochloride, 50 mM
NaH2PO4, pH 8.0) for the denaturing extraction of His-
tagged proteins. Cells were lysed for 1 h at room
temperature or overnight at 48C with gentle stirring. The
lysate was cleared by centrifugation (20 min 4000 g) and
MDM2 phosphorylation by CK2
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the supernatant was subjected to metal chelate chromato-
graphy on a Ni2+ agarose column as described (Appel et
al., 1995). His-tagged proteins bound to the matrix were
eluted by shifting the pH value of the lysis buer to pH
5.0. Eluted proteins were dialysed against 50 mM Tris-HCl
pH 8.0, 100 mM NaCl, 0.1% Tween 20.
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